Matching articles for "Lumipulse G"

Two New Blood Tests for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • November 23, 2026;  (Issue 1768)
Two new blood tests for biomarkers that correlate with brain amyloid beta pathology have been cleared by the FDA to aid in the diagnosis of Alzheimer's disease (AD): Elecsys Phospho-Tau (217P) Plasma assay...
Two new blood tests for biomarkers that correlate with brain amyloid beta pathology have been cleared by the FDA to aid in the diagnosis of Alzheimer's disease (AD): Elecsys Phospho-Tau (217P) Plasma assay (Roche) and PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood tests for AD biomarkers are listed in Table 1. The amyloid beta-directed antibodies lecanemab (Leqembi, and others) and donanemab (Kisunla) are available for treatment of AD in patients with mild cognitive impairment or mild dementia who have confirmed brain amyloid pathology.
Med Lett Drugs Ther. 2026 Nov 23;68(1768):185-6 | Show Full IntroductionHide Full Introduction